Altox

Database / Pharmaceutical impurity

Pharmaceutical impurity

N-[[trans-4-(1-Methylethyl)cyclohexyl]carbonyl]-D-phenylalanyl-D-phenylalanine Dicyclohexylammonium Salt (Nateglinide IPP Impurity Dicyclohexylammonium Salt)

N-[[trans-4-(1-Methylethyl)cyclohexyl]carbonyl]-D-phenylalanyl-D-phenylalanine Dicyclohexylammonium Salt (Nateglinide IPP Impurity Dicyclohexylammonium Salt) is listed in the pharmaceutical impurity collection. Its represented structure has formula C40H59N3O4 and a calculated molecular weight of 645.93 g/mol.

2D chemical structure

N H O H N O H N O O H ( R ) ( R )

Chemical identity

Catalog name
N-[[trans-4-(1-Methylethyl)cyclohexyl]carbonyl]-D-phenylalanyl-D-phenylalanine Dicyclohexylammonium Salt (Nateglinide IPP Impurity Dicyclohexylammonium Salt)
Common name
N-[[trans-4-(1-Methylethyl)cyclohexyl]carbonyl]-D-phenylalanyl-D-phenylalanine Dicyclohexylammonium Salt (Nateglinide IPP Impurity Dicyclohexylammonium Salt)
Chemical name
N-cyclohexylcyclohexanamine;(2R)-3-phenyl-2-[[(2R)-3-phenyl-2-[(4-propan-2-ylcyclohexanecarbonyl)amino]propanoyl]amino]propanoic acid
CAS
Not available
SMILES
C1CCC(NC2CCCCC2)CC1.CC(C)C1CCC(C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@H](Cc2ccccc2)C(=O)O)CC1
InChI
InChI=1S/C28H36N2O4.C12H23N/c1-19(2)22-13-15-23(16-14-22)26(31)29-24(17-20-9-5-3-6-10-20)27(32)30-25(28(33)34)18-21-11-7-4-8-12-21;1-3-7-11(8-4-1)13-12-9-5-2-6-10-12/h3-12,19,22-25H,13-18H2,1-2H3,(H,29,31)(H,30,32)(H,33,34);11-13H,1-10H2/t22?,23?,24-,25-;/m1./s1
InChIKey
UVXHEOAJNCWUHA-HKTCILMASA-N
Associated API
Matrix - API Family Nateglinide

Record ID: A3887d8ef9293

Computed properties

C40H59N3O4 Molecular formula
645.929 g/molMolecular weight
645.4506 DaMonoisotopic exact mass
107.53 ŲTopological polar surface area
7.2298 Calculated LogP (Wildman–Crippen)
188.9569 cm³/molMolar refractivity (Wildman–Crippen)
4 countHydrogen-bond acceptors
4 countHydrogen-bond donors

Descriptors are calculated from the displayed SMILES. Calculated LogP is not a measured partition coefficient or a pH-specific LogD. The SMILES contains 2 disconnected components. Calculations retain all represented components.

Molecular descriptor profile

Descriptor radar

Mol. weight LogP TPSA HBA HBD Rotatable 25 50 75 100

Structural feature counts

0 4 8 12 Count H-bond acceptors H-bond donors Rotatable bonds Rings Aromatic rings Stereo centers

Element composition

C H N O 0 15 30 45 60 Number of atoms

Radar scale: 0–100 percentile within 25,771 distinct represented structures in this release, using the midpoint rank for ties. Larger values indicate a higher descriptor rank, not greater safety or toxicity. Element counts include hydrogen and combine isotopes under each element.

Radar values and percentile reference
DescriptorValuePercentile
Molecular weight645.92993.66
Calculated LogP (Wildman–Crippen)7.229897.44
Topological polar surface area107.5376.21
Hydrogen-bond acceptors450.68
Hydrogen-bond donors489.70
Rotatable bonds (strict)1293.56

Complete molecular descriptors

PropertyCalculated valueUnit / type
Molecular formulaC40H59N3O4dimensionless
Molecular weight645.929g/mol
Monoisotopic exact mass645.4506Da
Topological polar surface area107.53Ų
Calculated LogP (Wildman–Crippen)7.2298dimensionless
Molar refractivity (Wildman–Crippen)188.9569cm³/mol
Hydrogen-bond acceptors4count
Hydrogen-bond donors4count
Rotatable bonds (strict)12count
Heavy atoms47count
Heteroatoms7count
Rings5count
Aromatic rings2count
Aliphatic rings3count
Saturated rings3count
Aromatic heterocycles0count
Aliphatic heterocycles0count
Saturated heterocycles0count
Aromatic carbocycles2count
Aliphatic carbocycles3count
Fraction of sp³ carbon atoms0.625fraction
Formal charge0e
Disconnected components2count
Isotopically specified atoms0count
Potential atom stereocenters2count
Unspecified atom stereocenters0count
Spiro atoms0count
Bridgehead atoms0count
Labute approximate surface area282.6236Ų
Valence electrons258count
Radical electrons0count
Bertz complexity1,184.4925index
Balaban J0index

Ring categories overlap and should not be summed. No toxicity result, PDE, HBEL or acceptable intake is inferred from these descriptors.

Toxicological services and resources for N-[[trans-4-(1-Methylethyl)cyclohexyl]carbonyl]-D-phenylalanyl-D-phenylalanine Dicyclohexylammonium Salt (Nateglinide IPP Impurity Dicyclohexylammonium Salt)

Qualification and safety assessment of N-[[trans-4-(1-Methylethyl)cyclohexyl]carbonyl]-D-phenylalanyl-D-phenylalanine Dicyclohexylammonium Salt (Nateglinide IPP Impurity Dicyclohexylammonium Salt)

Explore toxicological qualification of N-[[trans-4-(1-Methylethyl)cyclohexyl]carbonyl]-D-phenylalanyl-D-phenylalanine Dicyclohexylammonium Salt (Nateglinide IPP Impurity Dicyclohexylammonium Salt) and ICH M7 mutagenic impurity assessment of N-[[trans-4-(1-Methylethyl)cyclohexyl]carbonyl]-D-phenylalanyl-D-phenylalanine Dicyclohexylammonium Salt (Nateglinide IPP Impurity Dicyclohexylammonium Salt) for evaluation of this impurity in its pharmaceutical context.

Where data gaps need to be addressed, resources include read-across assessment for N-[[trans-4-(1-Methylethyl)cyclohexyl]carbonyl]-D-phenylalanyl-D-phenylalanine Dicyclohexylammonium Salt (Nateglinide IPP Impurity Dicyclohexylammonium Salt) and acceptable intake and limit justification for N-[[trans-4-(1-Methylethyl)cyclohexyl]carbonyl]-D-phenylalanyl-D-phenylalanine Dicyclohexylammonium Salt (Nateglinide IPP Impurity Dicyclohexylammonium Salt). The relevant approach depends on the available evidence, exposure and duration of use.

Related Altox services and technical resources

Identity sources and calculation method

Identifiers originate from the source catalogues and available public identity records. InChI and InChIKey on this page are generated from the displayed SMILES. RDKit validation checks the molecular representation; it does not independently verify every catalogue assignment.

Discuss an assessment for N-[[trans-4-(1-Methylethyl)cyclohexyl]carbonyl]-D-phenylalanyl-D-phenylalanine Dicyclohexylammonium Salt (Nateglinide IPP Impurity Dicyclohexylammonium Salt)

Explore Altox services and software through the Altox Pharma-Hub.